Meeting
2015 ASCO Annual Meeting
Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
Authors
Payal Deepak Shah
Memorial Sloan Kettering Cancer Center, New York, NY
Payal Deepak Shah , Sarat Chandarlapaty , Maura N. Dickler , Gary Ulaner , Stephen James Zamora , Valentina Sterlin , Alexia Iasonos , Christina Marie Coughlin , Alex Morozov , Joy Ero , Neal Rosen , Teresa Gilewski , Monica Nancy Fornier , Nancy T. Sklarin , Michael F. Berger , Mary Ellen Moynahan , Clifford A. Hudis , Jose Baselga , Shanu Modi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT02167854
Citation
J Clin Oncol 33, 2015 (suppl; abstr 590)
DOI
10.1200/jco.2015.33.15_suppl.590
Abstract #
590
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).
First Author: Gargi D. Basu
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
Poster
2011 ASCO Annual Meeting
Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.
First Author: D. Gajria
Poster
2022 ASCO Annual Meeting
![Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).](https://d201v5jt9ylckg.cloudfront.net/288/14358/211355/211355_A1369_poster_pv.jpg)
Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).
First Author: Fabrice Andre